Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
Purpose
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.
Condition
- Atopic Dermatitis
Eligibility
- Eligible Ages
- Between 12 Years and 89 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Participants may be eligible if they: - Are 12 to 89 years old. - Have been diagnosed with atopic dermatitis (eczema). - Have had at least one atopic dermatitis flare within the past 2 months. - Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits. - If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study.
Exclusion Criteria
Participants may not be eligible if they: - Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements. - Do not have suitable skin areas for study measurements. - Have another skin condition that may affect study assessments. - Are pregnant.
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Recruiting Locations
Phoenix, Arizona 85006
Las Vegas, Nevada 89144
Portsmouth, New Hampshire 03801
Missouri City, Texas 77459
Harrison Nguyen, MD, MBA, MPH, DTM&H FAAD
More Details
- Status
- Recruiting
- Sponsor
- Castle Biosciences Incorporated
Detailed Description
Atopic dermatitis (AD), also called eczema, is a skin condition associated with repeated periods of worsening symptoms known as flares. Researchers believe that changes in skin barrier function may occur before visible skin changes or symptoms develop. The investigational Nevisense Go device uses Electrical Impedance Spectroscopy (EIS), which measures electrical properties of the skin related to skin barrier function. Previous studies using EIS have shown associations between impedance measurements and skin barrier changes in AD. This study will collect EIS measurements from affected and unaffected skin over time to evaluate whether these measurements may help estimate the likelihood of AD flare onset before visible signs or symptoms occur. The study is observational because device measurements will not be used to guide participant treatment or clinical care during study participation.